Date:
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone.
The New England Journal of Medicine: Search Results in Gastroenterology
Medio de comunicación libre e independiente que busca informar transmitiendo las últimas noticias tanto en técnologia, ciencia, economía, sociedad, política y el mundo.
© 2020 Univciencia. All Rights Reserved.
